TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percentage of Participants Prematurely Discontinuing Study Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of OME
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pressor response to exogenous noradrenaline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Patients Who Experienced a Dose-Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: CA19-9 Clinical Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to Objective Disease Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: unit cost per malaria case diagnosed and treated
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: total savings associated with treatment of confirmed malaria cases
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Assessment of Core Stabilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HgA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diabetes Distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Piperacillin Pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal Nerve Fiber Layer Thickness in anterior uveitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Retinal Nerve Fiber Layer Thickness in intermediate uveitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline Retinal Nerve Fiber Layer Thickness in anterior uveitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline Retinal Nerve Fiber Layer Thickness in intermediate uveitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of lung cancer cases detected early
Endpoint domain: Mortality/survival
Primary endpoint: Number of interval lung cancer cases
Endpoint domain: Mortality/survival
Primary endpoint: Change in socialization subscale scores of the Vineland Adaptive Behavior Scales (VABS-III)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in Parent Rated Social Responsiveness Scale 2 (SRS-2)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: National Institutes of Health Stroke Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Postural Assessment Scale for Stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke Rehabilitation Assessment of Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score at 15 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful catheter ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Major and Clinically Relevant Non-Major Bleeding Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of phenylalaninemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum Hemoglobin A1C Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum High Sensitivity C-Reactive Protein (hsCRP) Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Haptoglobin Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean of Circulating Angiogenic Cells in the Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Dysphagia Outcome and Severity Scale (DOSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of CMOR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type CMOR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of CMOR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leader Self-Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Spontaneous acceptance of the initial pre-calculation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Incidence of symptomatic intracranial hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Discriminatory ability of MCG scores for ACS diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maternal Plasma Concentrations of Buprenorphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal Breast Milk Concentrations of Buprenorphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant Plasma Concentrations of Buprenorphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in baseline Mental health distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Uterine arteries blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 6 months rate of progression free survival
Endpoint domain: Mortality/survival
Primary endpoint: radiographic marginal bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Steroid receptors expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: binocular visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Sensitivity (D-prime) to Novel Speech Sounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Auditory Category Learning Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Novel Auditory Word Learning Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Eyberg Child Behavior Inventory (ECBI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Strengths and Difficulties SDQ
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Spence Child Anxiety Scale-Preschool Version (SCAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Brief Symptom Inventory (BSI-18)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Patient Health Questionnaire (PHQ9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Parenting Stress Index (PSI-SF)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: increase of edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain evaluation using visual analog scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: trismus measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall survival from day of surgery
Endpoint domain: Mortality/survival
Primary endpoint: Safety and toleration assessed by adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: CogState at followup
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Daily Drinking Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Alcohol-Related Consequences
Endpoint domain: Adverse events/effects
Primary endpoint: Alcohol Demand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed Reward Discounting
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Erectile Function domain score of the IIEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in response for sexual encounter profile (SEP) question 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in response for sexual encounter profile (SEP) question 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of gall bladder sludge or gallstones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in plasma levels of Specific Coagulation Factors -VIII, X, XIII, TPA and PAI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of eligible participants willing to be randomised
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Freedom From Major Adverse Cardiac and Cerebrovascular Events (MACCE)
Endpoint domain: Adverse events/effects
Primary endpoint: Technical feasibility of USPIO-MRI of the chest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stability of orthodontic mini-implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intracranial progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Heavy Drinking Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended Phase 2 Dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Long-term safety and tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under Curve From 0 to Infinity (AUC0-infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal and neonatal outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cue- and MA-induced craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mini Mental State Examination
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Clinical laboratory safety tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective Units of Distress Scale (SUDS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PTSD Checklist (PCL)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: self-management level
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area under the curve at steady state (AUCss) of plasma IDX320
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed concentration (Cmax) of plasma IDX320
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trough concentration (Ctrough) of plasma IDX320
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numerical pain rating scale (NPRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Evolution of pregnancies in the first trimester
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change from baseline intraocular pressure (IOP) at 08:00 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline intraocular pressure (IOP) at 12:00 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Endogenous Thrombin Potential (ETP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Primary un-assisted patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: transition times to oral feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: transition times to full breast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: the weight of the babies when they started oral nutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Achieve USDA-recommended dietary intake based on five major food groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fractional anisotropy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 20% improvement based on the ACR criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in obsessions and compulsions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of YH4808
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of YH4808
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic reliability of prolonged wireless pH monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Comparison of oesophago-gastric junction distensibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Subjects Who Developed a Postoperative Pancreatic Duct Leak
Endpoint domain: Adverse events/effects
Primary endpoint: Cl
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vd
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoscopic Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with serious and non-serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Neutralization of endogenous VEGF in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of hVEGF26-104/RFASE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Understanding
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Patient Distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: CAQ Appropriateness and Acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Anxiety Sensitivity Index-3 (ASI-3)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Acute pulmonary edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: remission rate of rectal bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Increase in lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: highest tolerable dose of VNP40101M
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Activation of the Arm and Hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Post-prandial SAA content on apoB containing lipoproteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Degree of insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood sample collection pre- and post-irradiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of questions correctly answered
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Endometrial cancer rate
Endpoint domain: Mortality/survival
Primary endpoint: Endometrial hyperplasia rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Stigma experienced by children
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevention of HPV infection
Endpoint domain: Mortality/survival
Primary endpoint: Estimated blood loss by hemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Estimated blood loss by hematocrit level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in Hamilton Rating Scale for Depression (HAM-D) score from baseline
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Korean version-California Verbal Learning Test (K-CVLT) total score from baseline
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in Visual Continuous Performance Test (CPT) total score from baseline
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in Raven Progressive Matrices (RPM) total score from baseline
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of patients with 18F-Raltegravir-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Whole-body distribution of radiolabeled 18F-Raltegravir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In Vivo Adipose Cell Formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total dose of analgesics required
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: DNA methylation in blood monocytes and lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Gene expression in blood monocytes and lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Scores on PHQ-9 Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of Injection site reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of menstrually associated migraine headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Occurrence of the first appropriate ICD shock
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Worsening heart failure hospitalizations or deaths from any cause
Endpoint domain: Mortality/survival
Primary endpoint: Reduction of adverse neurodevelopmental sequel
Endpoint domain: Adverse events/effects
Primary endpoint: Change in School Night Sleep Onset Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Non-school Night Sleep Onset Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Dim Light Melatonin Onset (DLMO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Dim Light Melatonin Onset (DLMO) Phase Shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety/tolerability of ECO-4601
Endpoint domain: Adverse events/effects
Primary endpoint: Determination of MTD of ECO-4601
Endpoint domain: Adverse events/effects
Primary endpoint: Determination of recommended dose for future studies of ECO-4601
Endpoint domain: Adverse events/effects
Primary endpoint: differences in limb alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Alzheimer's Disease assessment scale-cognitive
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: clinical dementia rating sum of boxes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Antibiotic use (short term)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Nights With Sensor Glucose Value ≤60 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical Global Impression (CGI) Item 4 (Side Effects)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Absolute Time Spent Off
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Healing assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of hypertension medication prescription
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Comfort Level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of Time Up Go test (TUG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood levels of Suppression Of Tumorigenicity 2 (ST2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood levels of Galectin-3 (Gal-3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enhanced Liver Fibrosis score (ELF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CMR imaging marker of fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spirometry measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: complete or partial remission of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with CMV reactivation
Endpoint domain: Adverse events/effects
Primary endpoint: Time to CMV reactivation
Endpoint domain: Adverse events/effects